Direct costs of radiotherapy for rectal cancer: a microcosting study
about
Neoadjuvant treatment for rectal cancer-A value-based proposition.A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practiceNeoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States.Can automation in radiotherapy reduce costs?
P2860
Direct costs of radiotherapy for rectal cancer: a microcosting study
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Direct costs of radiotherapy for rectal cancer: a microcosting study
@ast
Direct costs of radiotherapy for rectal cancer: a microcosting study
@en
type
label
Direct costs of radiotherapy for rectal cancer: a microcosting study
@ast
Direct costs of radiotherapy for rectal cancer: a microcosting study
@en
prefLabel
Direct costs of radiotherapy for rectal cancer: a microcosting study
@ast
Direct costs of radiotherapy for rectal cancer: a microcosting study
@en
P2093
P2860
P1476
Direct costs of radiotherapy for rectal cancer: a microcosting study
@en
P2093
Alan Ó Céilleachair
Ciaran O'Neill
Linda Sharp
Máiréad Skally
Paul Hanly
P2860
P2888
P356
10.1186/S12913-015-0845-9
P577
2015-05-02T00:00:00Z
P5875
P6179
1034120334